Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)

INTRODUCTION: A previous phase 2b study supported the use of the 5‐HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia. A phase 3 study, MINDSET, was performed to test this hypothesis. METHODS: MINDSET was a global, double‐blind, randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Frederick M., Mo, Yi, Sabbagh, Marwan, Solomon, Paul, Boada, Merce, Jones, Roy W., Frisoni, Giovanni B., Grimmer, Timo, Dubois, Bruno, Harnett, Mark, Friedhoff, Sarah R., Coslett, Shari, Cummings, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165732/
https://www.ncbi.nlm.nih.gov/pubmed/34095437
http://dx.doi.org/10.1002/trc2.12136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165732/
https://www.ncbi.nlm.nih.gov/pubmed/34095437
http://dx.doi.org/10.1002/trc2.12136

Ejemplares similares